124 related articles for article (PubMed ID: 15036947)
1. Successful treatment with imatinib mesylate of hypereosinophilic syndrome (chronic eosinophilic leukemia) with myelofibrosis.
Ishii Y; Ito Y; Kuriyama Y; Tauchi T; Ohyashiki K
Leuk Res; 2004 May; 28 Suppl 1():S79-80. PubMed ID: 15036947
[No Abstract] [Full Text] [Related]
2. Soft tissue and skeletal involvement in FIP1L1-PDGFR-alpha positive chronic eosinophilic leukemia: imatinib mesylate may induce complete molecular and imaging remission.
Malagola M; Martinelli G; Rondoni M; Ottaviani E; Piccaluga PP; Ricci P; Visani G; Baccarani M
Haematologica; 2004 Aug; 89(8):ECR25. PubMed ID: 15339694
[No Abstract] [Full Text] [Related]
3. Imatinib mesylate treatment in two patients with idiopathic hypereosinophilic syndrome.
Payne SM; Kovacs MJ
Ann Pharmacother; 2004; 38(7-8):1215-8. PubMed ID: 15187212
[TBL] [Abstract][Full Text] [Related]
4. Treatment of idiopathic hypereosinophilic syndrome with imatinib mesylate.
Garg A; Duggal L; Aggarwal S; Jain N
J Assoc Physicians India; 2006 Nov; 54():883-6. PubMed ID: 17249259
[TBL] [Abstract][Full Text] [Related]
5. Successful treatment of advanced idiopathic myelofibrosis with imatinib mesylate.
Stagno F; Consoli C; Mannino F; Guglielmo P; Giustolisi R
Eur J Haematol; 2004 Aug; 73(2):147-8. PubMed ID: 15245516
[No Abstract] [Full Text] [Related]
6. Bullous pemphigoid associated with hypereosinophilic syndrome: simultaneous response to imatinib.
Hofmann SC; Technau K; Müller AM; Lübbert M; Bruckner-Tuderman L
J Am Acad Dermatol; 2007 May; 56(5 Suppl):S68-72. PubMed ID: 17097375
[TBL] [Abstract][Full Text] [Related]
7. Treatment of a case of pediatric hypereosinophilic syndrome with anti-interleukin-5.
Mehr S; Rego S; Kakakios A; Kilham H; Kemp A
J Pediatr; 2009 Aug; 155(2):289-91. PubMed ID: 19619754
[TBL] [Abstract][Full Text] [Related]
8. Imatinib-mesylate for all patients with hypereosinophilic syndrome?
Musto P; Perla G; Minervini MM; Carella AM; Coco FL; Catalano G
Leuk Res; 2004 Jul; 28(7):773-4. PubMed ID: 15158099
[No Abstract] [Full Text] [Related]
9. [Idiopathic hypereosinophilic syndrome: toward a new molecular-targeted therapy and a new cytomorphological and molecular definition].
Moles MP; Landry J; Roche-Lestienne C; Godon A; Schmidt-Tanguy A; Gardembas M; Le Clech C; Verret JL; Zandecki M; Blanchet O
Ann Biol Clin (Paris); 2005; 63(3):317-22. PubMed ID: 15951264
[TBL] [Abstract][Full Text] [Related]
10. Imatinib mesylate for the treatment of hypereosinophilic syndromes.
Antoniu SA
Curr Opin Investig Drugs; 2006 Nov; 7(11):980-4. PubMed ID: 17117585
[TBL] [Abstract][Full Text] [Related]
11. Improvement of cardiac function, mitral regurgitation and pulmonary hypertension in a patient with chronic eosinophilic leukemia (CEL) after low dose imatinib therapy.
Krauth MT; Binder T; Ohler L; Jäger U; Valent P
Leuk Res; 2008 Nov; 32(11):1779-83. PubMed ID: 18417214
[No Abstract] [Full Text] [Related]
12. Long-term remission of lymphocytic hypereosinophilic syndrome with imatinib mesylate.
Christoforidou A; Kotsianidis I; Margaritis D; Anastasiadis A; Douvali E; Tsatalas C
Am J Hematol; 2012 Jan; 87(1):131-2. PubMed ID: 21919038
[No Abstract] [Full Text] [Related]
13. Successful treatment with imatinib in a patient with chronic eosinophilic leukemia not otherwise specified.
Iurlo A; Fracchiolla NS; Ferla V; Cassin R; Gottardi E; Beghini A; Gianelli U; Spinelli O; Cortelezzi A
J Clin Oncol; 2014 Apr; 32(10):e37-9. PubMed ID: 24449233
[No Abstract] [Full Text] [Related]
14. Treatment of hypereosinophilic syndrome with imatinib mesilate.
Gleich GJ; Leiferman KM; Pardanani A; Tefferi A; Butterfield JH
Lancet; 2002 May; 359(9317):1577-8. PubMed ID: 12047970
[TBL] [Abstract][Full Text] [Related]
15. Reversal of hypereosinophilic syndrome and lymphomatoid papulosis with mepolizumab and imatinib.
Koury MJ; Newman JH; Murray JJ
Am J Med; 2003 Nov; 115(7):587-9. PubMed ID: 14599646
[No Abstract] [Full Text] [Related]
16. [Treatment of idiopathic hypereosinophilic syndrome with imatinib].
Sørensen AL; Larsen H
Ugeskr Laeger; 2008 Jan; 170(4):254. PubMed ID: 18282461
[TBL] [Abstract][Full Text] [Related]
17. Imatinib therapy in Hypereosinophilic Syndrome: a case of molecular remission.
Cervetti G; Galimberti S; Carulli G; Petrini M
Leuk Res; 2005 Sep; 29(9):1097-8. PubMed ID: 16038739
[No Abstract] [Full Text] [Related]
18. Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome.
Klion AD; Robyn J; Akin C; Noel P; Brown M; Law M; Metcalfe DD; Dunbar C; Nutman TB
Blood; 2004 Jan; 103(2):473-8. PubMed ID: 14504092
[TBL] [Abstract][Full Text] [Related]
19. Significance of myelofibrosis in early chronic-phase, chronic myelogenous leukemia on imatinib mesylate therapy.
Kantarjian HM; Bueso-Ramos CE; Talpaz M; O'Brien S; Giles F; Faderl S; Wierda W; Rios MB; Shan J; Cortes J
Cancer; 2005 Aug; 104(4):777-80. PubMed ID: 15971197
[TBL] [Abstract][Full Text] [Related]
20. Case report: rapid and complete control of idiopathic hypereosinophilia with imatinib mesylate.
Schaller JL; Burkland GA
MedGenMed; 2001 Sep; 3(5):9. PubMed ID: 11698916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]